Panpan Feng Selected Research

Colitis

1/2021	The m6A Reader IGF2BP2 Regulates Macrophage Phenotypic Activation and Inflammatory Diseases by Stabilizing TSC1 and PPARγ.
1/2017	Inhibition of Epithelial TNF-α Receptors by Purified Fruit Bromelain Ameliorates Intestinal Inflammation and Barrier Dysfunction in Colitis.
1/2017	Corrigendum: Inhibition of Epithelial TNF-α Receptors by Purified Fruit Bromelain Ameliorates Intestinal Inflammation and Barrier Dysfunction in Colitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Panpan Feng Research Topics

Disease

6	Inflammation (Inflammations) 10/2023 - 01/2017
4	Neoplasms (Cancer) 01/2022 - 01/2020
3	Pulmonary Hypertension 07/2023 - 01/2020
3	Colitis 01/2021 - 01/2017
2	Body Weight (Weight, Body) 10/2023 - 01/2022
2	Familial Primary Pulmonary Hypertension 07/2023 - 01/2022
2	Heart Failure 12/2022 - 03/2019
2	Fibrosis (Cirrhosis) 01/2020 - 03/2019
1	Pelvic Pain 10/2023
1	Prostatitis 10/2023
1	Cardiotoxicity 12/2022
1	Ischemia 10/2022
1	Infarction (Infarctions) 01/2022
1	Colonic Neoplasms (Colon Cancer) 01/2022
1	Hypoxia (Hypoxemia) 01/2022
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2022
1	Dysbiosis 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 10/2021
1	Pulmonary Embolism 07/2021
1	Venous Thromboembolism 07/2021
1	Tuberous Sclerosis 1 01/2021
1	Malaria 01/2020
1	Vascular Remodeling 01/2020
1	Infections 09/2019
1	Hyperkalemia 03/2019
1	Gynecomastia 03/2019
1	Sepsis (Septicemia) 12/2018
1	Dwarfism 02/2017
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2017
1	Ulcer 01/2017

Drug/Important Bio-Agent (IBA)

3	Proteins (Proteins, Gene)FDA Link 10/2022 - 01/2022
3	N-methyladenosineIBA 01/2022 - 01/2021
3	6-methyladenineIBA 01/2022 - 10/2021
2	EnzymesIBA 01/2022 - 10/2021
2	MonocrotalineIBA 01/2022 - 01/2020
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2021
2	Insulin-Like PeptidesIBA 01/2022 - 01/2021
2	Carrier Proteins (Binding Protein)IBA 01/2022 - 01/2021
2	CytokinesIBA 12/2018 - 01/2017
2	fruit bromelainIBA 01/2017 - 01/2017
1	gypenosideIBA 10/2023
1	Isoproterenol (Isoprenaline)FDA LinkGeneric 10/2023
1	DisintegrinsIBA 07/2023
1	ThrombospondinsIBA 07/2023
1	Metalloproteases (Metalloproteinases)IBA 07/2023
1	AnthracyclinesIBA 12/2022
1	baicalinIBA 12/2022
1	Antineoplastic Agents (Antineoplastics)IBA 12/2022
1	baicaleinIBA 12/2022
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 10/2022
1	ImmunosorbentsIBA 01/2022
1	gossypinIBA 01/2022
1	RNA (Ribonucleic Acid)IBA 10/2021
1	CeramidesIBA 10/2021
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 07/2021
1	Vasodilator Agents (Vasodilators)IBA 01/2021
1	Interleukin-4 (Interleukin 4)IBA 01/2021
1	Dextran SulfateIBA 01/2021
1	Phosphodiesterase 5 InhibitorsIBA 01/2021
1	artenimol (dihydroartemisinin)IBA 01/2020
1	artemisinin (artemisinine)IBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 09/2019
1	Spironolactone (Aldactone)FDA LinkGeneric 03/2019
1	procollagen type I carboxy terminal peptide (PICP)IBA 03/2019
1	procollagen Type III-N-terminal peptide (PIIP)IBA 03/2019
1	LipopolysaccharidesIBA 12/2018
1	Cathepsin BIBA 12/2018
1	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2018
1	ChlorophyllIBA 02/2017
1	Sulfonic AcidsIBA 01/2017
1	Type I Tumor Necrosis Factor ReceptorsIBA 01/2017
1	Type II Tumor Necrosis Factor ReceptorsIBA 01/2017

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2017
1	Extracorporeal Shockwave Therapy 10/2023
1	Myofascial Release Therapy 10/2023
1	Immunotherapy 01/2022
1	Artificial Respiration (Mechanical Ventilation) 01/2021